| Literature DB >> 36062145 |
Guangyao Li1,2, Yuling Shi3, Lu Zhang1, Chuanghui Yang1, Ting Wan4, Hang Lv5, Wenxuan Jian2, Jinghu Li6, Min Li1.
Abstract
Background and purpose: Acupuncture is widely used in clinical practice for the treatment of vascular diseases. However, the protocol, efficacy, and mechanism of acupuncture in animal models of vascular dementia are still controversial. Based on the above problems, we initiated this comprehensive study.Entities:
Keywords: acupuncture; acupuncture mechanism; acupuncture protocol; animal studies; morris water maze; network meta-analysis; vascular dementia
Year: 2022 PMID: 36062145 PMCID: PMC9434110 DOI: 10.3389/fnagi.2022.952181
Source DB: PubMed Journal: Front Aging Neurosci ISSN: 1663-4365 Impact factor: 5.702
Figure 1Study characteristics. (A) Methods of surgical modeling, (B) Total number of modeling and the number of successful modeling, (C) Frequency of acupoint use, (D) Total course of treatment, (E) Frequency of acupoint combination. 2VO, Two - Vessel Occlusion or Bilateral Common Carotid Artery Occlusion; 4VO, Four-Vessel Occlusion; MCAO, Middle Cerebral Artery Occlusion; EO, Embolic occlusion, *P < 0.05 (Modeling success rate of MCAO VS 2VO, EO and 4VO, MCAO had the highest success rate). #P < 0.05 (Modeling success rate of 2VO VS 4VO and EO VS 4VO, no difference between 2VO and EO, and the lowest is 4VO).
Figure 2Network graph of morris water maze. Escape latency (A), Number of crossings (B), Time spent in target quadrant (C), Swimming speed (D). Gn, Normal group; Gs, Sham-operated group; Gi, Impaired group; Ga, acupuncture group; Gna, Non-acupoint group; Gm, Medicine group.
Network meta-analysis of MWM.
|
| |||||
| Ga | |||||
| −25.87 (−30.75, −21.12) | Gi | ||||
| 4.35 (−6.32, 14.48) | 30.09 (19.58, 40.46) | Gm | |||
| 13.73 (5.76, 21.88) | 39.58 (31.44, 47.53) | 9.60 (−2.51, 21.54) | Gn | ||
| −15.73 (−23.30, −8.15) | 10.16 (2.59, 17.66) | −19.99 (−32.00, −7.53) | −29.40 (−39.26, −19.82) | Gna | |
| 6.79 (1.92, 11.69) | 32.68 (27.80, 37.61) | 2.58 (−7.88, 13.19) | −6.92 (−15.18, 1.34) | 22.54 (15.14, 29.90) | Gs |
|
| |||||
| Ga | |||||
| 2.63 (1.94, 3.34) | Gi | ||||
| 0.09 (−1.09, 1.32) | −2.54 (−3.73, −1.32) | Gm | |||
| −1.29 (−2.41, −0.17) | −3.91 (−5.05, −2.81) | −1.39 (−2.87, 0.09) | Gn | ||
| 1.03 (−0.36, 2.41) | −1.61 (−3.01, −0.21) | 0.93 (−0.80, 2.65) | 2.32 (0.70, 3.92) | Gna | |
| −1.31 (−2.04, −0.57) | −3.95 (−4.69, −3.20) | −1.41 (−2.70, −0.18) | −0.03 (−1.22, 1.15) | −2.34 (−3.75, −0.93) | Gs |
|
| |||||
| Ga | |||||
| 7.92 (4.45, 11.48) | Gi | ||||
| −8.42 (−14.52, −2.65) | −16.35 (−22.26, −10.64) | Gn | |||
| 7.68 (3.35, 12.23) | −0.25 (−4.54, 4.18) | 16.13 (9.79, 22.44) | Gna | ||
| −5.36 (−9.03, −1.74) | −13.29 (−16.88, −9.69) | 3.09 (−2.80, 9.03) | −13.03 (−17.48, −8.53) | Gs | |
|
| |||||
| Ga | |||||
| 0.20 (−1.22, 1.71) | Gi | ||||
| 1.87 (−0.76, 4.24) | 1.58 (−0.75, 4.07) | Gn | |||
| 0.11 (−1.38, 1.52) | −0.34 (−1.90, 1.06) | −2.08 (−4.55, 0.42) | Gna | ||
| 0.24 (−1.51, 1.81) | −0.05 (−1.65, 1.52) | −1.74 (−4.66, 0.55) | 0.18 (−1.35, 1.82) | Gs | |
.
Figure 3Rank probability of interventions. Escape latency (A), Number of crossings (B). Gn, Normal group; Gs, Sham-operated group; Gi, Impaired group; Ga, acupuncture group; Gna, Non-acupoint group; Gm, Medicine group.
Figure 4The main mechanism of acupuncture in animal models of VD. EA, electroacupuncture; MA, manual acupuncture. Synapse function: LTP (Long-term Potential), AVP (arginine vasopressin), β-EP (β-endorphine), SS (somatostatin), ACh (acetylcholine), HVA (homovanillic acid), DA (dopamine), DOPAC (Dihydroxyphenylaceticacid), 5-HT (5-hydroxytryptamine),EP (Epinephrine), nAChR (Nicotinic-Acetylcholine receptor), D1/D5R (dopamine 1/ dopamine5 receptor), NMDAR (N-methyl-D-aspartate receptor), AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor), GABAAR (γ-amino-butyric acid type A receptor), 5-HT1AR (postsynaptic serotonin (1A) receptors), PSD-95 (postsynaptic density-95). signal pathways: CBF (cerebral blood flow), Ang-1 (Angiopoietin-1), VEGF (vascular endothelial growth factor), TLR4 (Toll Like Receptor 4), MyD88 (myeloid differentiation factor 88), NF-κB (nuclear factor-kappa B), α7nAChR (alpha-7 nicotinic acetylcholine receptor), JAK2 (Janus Kinase 2), STAT3 (Signal Transducer and Activator of Transcription 3), TNF-α (Tumor Necrosis Factor-α), IL-4 (interleukin 4), IL-10 (interleukin 10), IL-1β (interleukin 1β), Nrf2 (Nuclear factor erythroid2-related factor2), ARE (antioxidant response element), HO-1 (heme oxygenase), NQO1 (NADP (H) quinone oxidoreductase), ROS (reactive oxygen species), MDA (Malon-dialdehyde), SOD (superoxide dismutase), GSH (glutathione), HMGB1 (mobility group protein B1), MMP (mitochondrial membrane potential), PI3K (phosphatidylinositol 3-kinase), AKT (protein kinase B), mTOR (mammalian target of rapamycin), Bcl-2 (B-cell lymphoma-2), JNK (c-Jun N-terminal kinase).